Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

2017

Do PCSK9 Monoclonal Antibodies plus SOC
Prevent Major Adverse Cardiovascular Events in
Adults with Hypercholesterolemia Compared to
Placebo Plus SOC?
Amy Doyle
Philadelphia College of Osteopathic Medicine

Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Cardiology Commons
Recommended Citation
Doyle, Amy, "Do PCSK9 Monoclonal Antibodies plus SOC Prevent Major Adverse Cardiovascular Events in Adults with
Hypercholesterolemia Compared to Placebo Plus SOC?" (2017). PCOM Physician Assistant Studies Student Scholarship. 398.
https://digitalcommons.pcom.edu/pa_systematic_reviews/398

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

Do PCSK9 monoclonal antibodies plus SOC prevent major adverse
cardiovascular events in adults with hypercholesterolemia
compared to placebo plus SOC?

Amy Doyle, PA-S
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW
In Partial Fulfillment of the Requirements For
The Degree of Master of Science
In
Health Sciences – Physician Assistant

Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

December 16, 2016

Doyle 2
PCSK9 Inhibitors & Hypercholesterolemia
ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not PCSK9
monoclonal antibodies plus SOC prevent major adverse cardiovascular events in adults with
hypercholesterolemia compared to placebo plus SOC.
Study Design: This review is using one double-blinded randomized controlled trial (RCT) and
two open-label RCTs investigating alirocumab and evolocumab, published in 2014 and 2015.
Data sources: Articles were found on PubMed, and were published in peer-reviewed journals in
English.
Outcome Measured: The outcome measured was major adverse cardiac events (MACE), which
included death, MI, hospitalization for unstable angina, revascularization, or cerebrovascular
event.
Results: Robinson, et al. showed a lower incidence of MACE in the alirocumab group compared
to the placebo group (p=0.02, CI 0.31-0.90) with a number needed to treat (NNT) of -62.
Sabatine, et al. showed a lower incidence of MACE in the evolocumab group compared to SOC
group (p=0.003, CI 0.28-0.78) with NNT of -93. Koren, et al. showed lower incidence of MACE
in the evolocumab group compared to SOC with NNT of -105.
Conclusions: The results of the three studies indicate that PCSK9 monoclonal antibodies
(alirocumab or evolocumab) prevented MACE when compared to placebo or SOC. More studies
could investigate which of the two drugs has better efficacy to prevent MACE and safety.
Further studies could be done to compare specific characteristics like those who are statinintolerant or those with familial hypercholesterolemia to patients already on a statin.
Key Words: hypercholesterolemia, alirocumab and cardiovascular events, evolocumab and
cardiovascular events
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INTRODUCTION
Hypercholesterolemia is multifactorial, with causes originating from genetic defects,
secondary to other disease, increasing age, diet, and lack of exercise. Hypercholesterolemia is
associated with an increased risk for cardiovascular disease, which is the most common cause of
death worldwide.1 Atherosclerosis due to hypercholesterolemia over time can lead to plaque
rupture and can cause myocardial infarction, cerebrovascular accident, angina pectoris,
mesenteric ischemia, and renal artery stenosis.1 This paper evaluates three randomized controlled
trials (RCTs) comparing the efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9)
monoclonal antibodies for the prevention of major adverse cardiac events (MACE).
There are approximately 26.5 million adults with known cardiovascular disease in the
U.S., with about 59% of these patients having dyslipidemia.2 About 73.5 million American
adults have an elevated low-density lipoprotein (LDL) level; and in 2009, there were 96 million
healthcare visits which included ordering a lipid panel.3 Therefore, most healthcare providers,
including physician assistants, will be involved in the care of patients with hypercholesterolemia
and its effects. The estimated cost of cardiovascular disease in the U.S. in 2010 was $273 billion,
and a MACE costs an average of $16,582.2 Despite the increase in medical technology and
cardiovascular medications over the past century, cardiovascular disease accounted for 40% of
deaths in high-income countries in 2010.1 This is likely due to the change in lifestyle and
increased age in high-income countries over this time period, and is expected to increase.4
PCSK9 monoclonal antibodies have been shown to reduce LDL cholesterol in patients
also treated with statins.5 Patients with elevated LDL cholesterol have twice the risk for
cardiovascular disease than patients without elevated LDL3, and this cardiovascular disease can
lead to a MACE due to atherosclerosis. Lipid-lowering therapy can improve endothelial
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dysfunction in the arterial lumen, correct abnormal vascular reactivity, and increase plaque
stability.4
Lifestyle changes are implemented in the recommended treatment and prevention of
hypercholesterolemia and MACE. These include a low-cholesterol diet, exercise, and weight
reduction. HMG-CoA reductase inhibitors (statins) have become the mainstay for treatment of
hypercholesterolemia.1 Some other treatments that have controversial outcome studies include:
bile acid sequestrants, nicotinic acid, fibric acid derivatives, and omega-3 fatty acids.1 While
statins have been shown to reduce MACE, there are still many patients on statins who have
cardiac events or whose risk remains high for cardiac events, and there are patients who are
statin-intolerant due to side effects.1 When PCSK9 interacts with the LDL receptor, LDL levels
increase. PCSK9 monoclonal antibodies act as an inhibitor of this interaction.1 PCSK9
monoclonal antibodies (alirocumab and evolocumab) have been shown to significantly reduce
LDL levels5,6,7, and reduction of LDL has been shown to lower cardiovascular risk. However, it
is not clear whether PCSK9 monoclonal antibodies prevent MACE.
OBJECTIVE
The objective of this selective systematic review is to determine whether or not PCSK9
monoclonal antibodies plus standard of care (SOC) prevent major adverse cardiovascular events
in adults with hypercholesterolemia compared to placebo plus SOC.
METHODS
One double-blinded randomized controlled trial (RCT) and two open-label RCTs were
used in this study. The population includes patients at least 18 years old with an LDL>70 mg/dl
and at least one of the following: coronary artery disease, coronary heart disease risk equivalent,
or familial hypercholesterolemia. The interventions were the PCSK9 monoclonal antibodies
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alirocumab or evolocumab, and the comparison was standard of care hypercholesterolemia
treatment which most commonly included a statin. The Robinson, et al. double blinded RCT
compared alirocumab to placebo for 78 weeks while both groups were being treated with a
maximum-tolerated dose of statins with or without other lipid-lowering therapy. The change in
LDL was calculated from baseline to week 24. A post-hoc analysis was done to assess MACE
between the two groups up to 78 weeks after baseline. The Sabatine, et al. open-label RCT
compared evolocumab plus SOC to SOC for 11.1 months. There was no placebo treatment. The
Koren, et al. open-label RCT compared evolocumab plus SOC to SOC for 12 months. Outcomes
measured for all 3 trials were MACE: death, MI, hospitalization for unstable angina,
revascularization, or cerebrovascular event. (See Table 1 for more details)
Keywords used in the research of this paper included: alirocumab and cardiovascular
events, evolocumab and cardiovascular events, and hypercholesterolemia. The articles were
found on PubMed, and were published in English in peer-reviewed journals. The three articles
were selected based on relevance to the objective, patient-oriented outcomes, and type of trial.
Inclusion criteria included: randomized controlled trial including adults with
hypercholesterolemia published after 2000, not researched by a previous PCOM student, and no
published Cochrane meta-analyses or systematic reviews on this topic. Exclusion criteria
included disease-oriented outcomes only. (See Table 1 for detailed inclusion/exclusion criteria
per study.) Robinson, et al. and Sabatine, et al. reported the following statistics: hazard ratio, pvalue, relative risk reduction (RRR), absolute risk reduction (ARR), and number need to treat
(NNT). Koren, et al. reported: RRR, ARR, and NNT.
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Table 1 – Demographics & characteristics of included studies
STUDY
TYPE #
AGE INCLUSION EXCLUSION
PTS
CRITERIA
CRITERIA
Robinson, Double 2341 60.4  >18 yrs old w/  Use of meds
20155
blinded
+
familial
that affect
RCT
10.4
hypercholestlipids
years erolemia,
 Plasmapharesis
old
CAD, or CHD
w/in 4 weeks
risk
MACE, CABG,
equivalent
uncontrolled
 LDL >70
arrhythmia,
 Current use of PCI, carotid
simvastatin,
surgery, PVD
atorvastatin,
intervention
or
w/in 3 months
rosuvastatin
 NYHA Class
III or IV
 SBP>180 or
DBP>110
 Hx of stroke
(hemorrhagic)
 Active optic
nerve disease
 Systemic
steroid use
 HRT
 HIV +
 Cancer w/in 5
years
Sabatine, Open
4465 >18  >18 years old  Adverse events
20156
Label
years with
in parent trial
RCT
old
hypercholest-  Unstable
erolemia
medical
Mean  Participation
condition
age=
in 1 of the
 Need of
58
following
unblinded lipid
years trials: Mendel
measurements
old
1 & 2,
for 1st 12 weeks
Laplace TIMI
57, Laplace 2,
Gauss 1 & 2,
Rutherford 1
& 2, Yukawa
1, Descartes,
Thomas 1 & 2

W/D
470

204

INTERVENTION
Alirocumab
150 mg as a
1 mL SC
injection
q2weeks

Evolocumab
140mg SC
q2weeks or
420mg SC
q4weeks
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Koren,
20147

Open
Label
RCT

1104 >18  >18 years old  Adverse events
years with
in parent trial
old
hypercholest-  Need of
erolemia
unblinded lipid
Mean  Participation
measurements
age=
in 1 of the
for 1st 12 weeks
56.4
following
years trials: Mendel,
old
Laplace TIMI
57, Gauss,
Rutherford

94

Evolocumab
420mg SC
q4weeks

OUTCOMES MEASURED
The outcomes measured in this paper are major adverse cardiovascular events, which
include the following: death, myocardial infarction, hospitalization for unstable angina,
revascularization, or cerebrovascular event. Any adverse event was reported using patientreported symptoms or events/hospitalizations, laboratory tests, vital signs, and EKG. These
events were reported either in person at office visits or via telephone.5,6,7
RESULTS
This review included one study comparing alirocumab plus a statin to placebo plus a
statin, and two studies comparing evolocumab to standard of care hypercholesterolemia
treatments. All the trials included adult patients with hypercholesterolemia. Two of the trials
included patients from one of many parent trials. Efficacy and safety were investigated in the
trials and were presented as dichotomous data, with the outcome of having a MACE or not.
The Robinson, et al. trial was a double-blinded RCT initially investigating the efficacy
and safety of long-term alirocumab treatment, and then investigating MACE associated with the
treatment group versus placebo group. There were 2431 patients enrolled and randomized in the
study over 320 sites worldwide. The participating patients were required to be on a maximumtolerated dose of statin and still have LDL >70 mg/dl at the time of screening. All patients were
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instructed to follow a cholesterol-lowering diet, exercise, and quit tobacco products. However,
tobacco use did not exclude patients from this study. Patients were excluded from participation if
they were using any product that affects lipid levels except statins or fenofibrate to ensure the
results were truly due to the study drug. Patients could not have received plasmapheresis within
two months prior to screening or plan to receive it during the study, so that LDL and other
bloodwork could be accurately obtained. Although patients in this trial must be at significant
cardiovascular risk, patients were excluded if they had a MACE, cardiac surgery, or
hospitalization within three months prior to screening. Patients were excluded if they were
NYHA Class III or IV heart failure within 12 months of screening or had systolic blood pressure
>180 mmHg or diastolic blood pressure >110 mmHg at time of screening. Other conditions that
excluded patients included: hemorrhagic stroke, active optic nerve disease, homozygous familial
hypercholesterolemia, known loss of function of PCSK9, cancer within five years, HIV
positivity, pregnancy/breastfeeding, or hepatitis B or C. Patients using systemic corticosteroids
or hormone replacement therapy were excluded, as well as those patients with any of the
following lab values: triglyceride levels >400 mg/dl as it becomes difficult to measure LDL,
eGFR <30 ml/min, HbA1c>10%, ALT or AST >3x upper normal limit, or CPK >3x upper
normal limit. This study used a mixed effects model to account for those patients lost to follow
up during the study – 20.9% of the alirocumab group and 18.5% of the placebo group were lost
to follow up. There was a lower incidence of MACE in the alirocumab group (1.7% of patients)
than in the placebo group (3.3% of patients) with a 95% confidence interval (0.31 to 0.90) and
p=0.02. The hazard ratio was 0.52, indicating that if a patient on a statin adds alirocumab to
his/her regimen, he/she will be about half as likely to have a MACE compared to the placebo
group on a statin. The NNT for this study was -62, indicating that for every 62 patients taking
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alirocumab in addition to a statin for the prevention of MACE, there was 1 fewer incidence of
MACE when compared to patients taking placebo plus a statin. Myalgia was the most significant
adverse event associated with the alirocumab group, with 5.4% of the treatment group and 2.9%
of the placebo group reporting myalgia; p=0.006. The number need to harm (NNH) for myalgia
was 40, indicating that for every 40 patients treated with alirocumab plus statin, 1 more
incidence of myalgia occurs compared to those taking placebo plus a statin. A higher percentage
of patients also reported neurocognitive disorders (amnesia, memory impairment, or confusional
state) in the alirocumab group when compared to the placebo group, 1.2% to 0.5%, respectively.
However, this result was not found to be significant, p=0.17.
The Sabatine, et al. trial was an open-label RCT conducted at 305 sites and was first
investigating the longer-term efficacy and safety of evolocumab, and then investigated MACE in
treatment versus SOC groups. There were 4465 patients randomized, with 3128 of those on a
statin. Inclusion criteria for this trial was completion of one of the parent studies without any
adverse events that caused discontinuation. The parent trials had slightly different inclusion
criteria but all had LDL of at least 75 mg/dl. Patients in the MENDEL parent trials were not on
any other lipid therapy. Patients in the LAPLACE, YUKAWA, DESCARTES, and THOMAS
parent trials were on statins. Patients in the GAUSS parent trials were statin-intolerant. Patients
in the RUTHERFORD parent trials had heterozygous familial hypercholesterolemia and were
taking a statin. Exclusion criteria for this trial were: any unstable medical condition, need for
unblinding of LDL results within first 12 weeks of the trial, or need for adjustment of
background lipid therapy within first 12 weeks of the trial. There were 4.88% of patients in the
treatment group and 3.96% in the SOC group that were lost to follow up. There was a lower
incidence of MACE in the evolocumab group (0.95% of patients) than in the SOC group (2.11%
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of patients) with a 95% confidence interval (0.28 to 0.78) and p=0.003. The hazard ratio was
0.47, indicating that if a patient adds evolocumab to his/her regimen, he/she will be about half as
likely to have a MACE compared to the SOC group. The NNT for this study was -93, indicating
that for every 93 patients taking evolocumab for the prevention of MACE, there was 1 fewer
incidence of MACE when compared to patients taking SOC hypercholesterolemia treatment. The
NNH for myalgia was 250, indicating that for every 250 patients treated with evolocumab, 1
more incidence of myalgia occurs compared to those taking SOC medications. There were 0.9%
of patients in the treatment group that reported neurocognitive events, compared to the 0.3% in
the SOC group.
The Koren, et al. trial was an open-label RCT conducted at 156 sites, also first
investigating efficacy and safety of evolocumab versus SOC, then investigating MACE. There
were 1104 patients randomized in this trial, inclusion criteria was participation in one of four
phase 2 parent trials without discontinuation due to adverse event. The parent trials included
MENDEL, LAPLACE, GAUSS, and RUTHERFORD. Exclusion criteria for this trial included:
any unstable medical condition, need for unblinding of LDL results within first 12 weeks of the
trial, or need for adjustment of background lipid therapy within first 12 weeks of the trial. There
were 7.47% in the treatment group and 10.6% in the SOC group that were lost to follow up
during the study. There was a lower incidence of MACE in the evolocumab group (1.2% of
patients) than in the SOC group (2.2% of patients). The NNT for this study was -105, indicating
that for every 105 patients taking evolocumab for the prevention of MACE, there was 1 fewer
incidence of MACE when compared to patients taking SOC hypercholesterolemia treatment. The
NNH for myalgia was -166, indicating that for every 166 patients treated with evolocumab, 1
fewer incidence of myalgia occurs compared to those taking SOC medications. This differs from
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the previous two studies in that more patients in the control group had myalgia than in the
treatment group. There were 1.09% of patients in the treatment group that reported amnesia or
memory impairment, compared to 0% in the SOC group.
Table 2 – Treatment effects
Robinson, et al., 20155

Sabatine, et al., 20156

Koren, et al., 20147

p-value

0.02

0.003

N/A

Confidence Interval

95% (0.31-0.90)

95% (0.28-0.78)

N/A

Hazard ratio

0.52

0.47

N/A

RRR

-0.485

-0.5323

-0.4378

ARR

-0.016

-0.0107

-0.0095

NNT

-62

-93

-105

Sabatine, et al., 20156

Koren, et al., 20147

Table 3 – Safety and adverse effects - Myalgia
Robinson, et al., 20155
p-value

0.006

N/A

N/A

RRR

0.862

0.067

-0.061

ARR

0.025

0.004

-0.006

NNH

40

250

-166

DISCUSSION
Alirocumab and evolocumab are monoclonal antibodies used to lower LDL cholesterol
levels that were approved by the FDA in 2015.8,9 Adverse effects reported for alirocumab
include: diarrhea, influenza, injection site reaction, myalgia, and cough.8 Adverse effects
reported for evolocumab include: nasopharyngitis, URI, dizziness, gastroenteritis, UTI,
influenza, local site reaction, and myalgia.9 Both reported contraindications with another
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monoclonal antibody, belimumab.8,9 Two studies showed an increase in the number of patients
who experienced myalgia who were on the experimental drug,5,6 while Koren, et al. showed
more patients in the control group reported myalgia.7 It is unknown if this myalgia is due to the
experimental drugs or due to the statins that most patients were on concurrently.
While all of these studies had a goal of evaluating LDL levels first, they also evaluated
the outcomes of using PCSK9 monoclonal antibodies. It was not previously known if these
agents prevented MACE, but all three trials showed a decrease in MACE when using the PCSK9
inhibiting drug compared to placebo or SOC over about one year. The Koren, et al. trial did not
provide p-values, confidence intervals, or hazard ratios, while the other two trials did include
these important statistical values. In addition, the Koren, et al. trial and the Sabatine, et al. trial
included patients from some of the same parent trials, so it is unknown if the same patients were
being accounted for twice in this review. While the monoclonal antibodies have the same
mechanism of action, the actual drug was different in the Robinson, et al. trial – alirocumab was
used instead of evolocumab. When looking at the NNT to prevent a MACE, it appears that
alirocumab is more effective. It also appears that the NNH for myalgia is lower in the alirocumab
study. However, more studies would have to be done to compare the two drugs. Finally, the
Robinson, et al. trial was double-blinded and was more controlled than the other two trials.
Therefore, the Sabatine, et al. and Koren, et al. trials may not be as valid.
CONCLUSIONS
This review showed that PCSK9 inhibitors prevented major adverse cardiac events when
compared to standard of care treatment in adults with hypercholesterolemia over about one
year.5,6,7 Longer-term studies could be done to see if safety and efficacy is maintained. Since
there were two different drugs being investigated, future double-blinded RCTs could be done to
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see which drug prevents more MACEs and which drug has more adverse events. There were also
different factors among the three studies that affected each patient’s individual risk for MACE,
like whether patients were also taking a statin during the study or whether patients had familial
hypercholesterolemia. If patients were already on statins, it is possible their risk would be lower
at the start of the study than a statin-intolerant patient. Overall, more studies would have to be
done to create a more-detailed picture of which specific populations would benefit greatly from
PCSK9 monoclonal antibodies.
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